NASDAQ:PDLI - PDL BioPharma Stock Price, News & Analysis

$2.57
+0.07 (+2.80 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
$2.49
Now: $2.57
$2.59
50-Day Range
$2.48
MA: $2.94
$3.23
52-Week Range
$2.25
Now: $2.57
$3.89
Volume2.95 million shs
Average Volume1.32 million shs
Market Capitalization$293.50 million
P/E Ratio6.95
Dividend YieldN/A
Beta0.66
PDL BioPharma, Inc acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PDLI
CUSIP69329Y10
Phone775-832-8500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$198.11 million
Cash Flow$0.5480 per share
Book Value$5.00 per share

Profitability

Net Income$-68,860,000.00

Miscellaneous

Employees105
Market Cap$293.50 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.


PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma declared that its Board of Directors has approved a stock buyback plan on Monday, September 24th 2018, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 27.3% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its shares are undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The biotechnology company had revenue of ($22.53) million for the quarter. PDL BioPharma had a positive return on equity of 6.61% and a negative net margin of 32.13%. View PDL BioPharma's Earnings History.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for PDL BioPharma.

What price target have analysts set for PDLI?

1 equities research analysts have issued 12 month price targets for PDL BioPharma's shares. Their predictions range from $3.00 to $3.00. On average, they anticipate PDL BioPharma's stock price to reach $3.00 in the next year. This suggests a possible upside of 16.7% from the stock's current price. View Analyst Price Targets for PDL BioPharma.

What is the consensus analysts' recommendation for PDL BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.

Has PDL BioPharma been receiving favorable news coverage?

Media stories about PDLI stock have trended positive this week, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. PDL BioPharma earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for PDL BioPharma.

Who are some of PDL BioPharma's key competitors?

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Opko Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), Canopy Growth (CGC), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Synergy Pharmaceuticals (SGYP), Bank of America (BAC) and Prospect Capital (PSEC).

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:
  • Mr. Dominique P. Monnet, CEO, Pres & Director (Age 58)
  • Mr. Peter S. Garcia, VP & CFO (Age 57)
  • Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
  • Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.68%), Vanguard Group Inc. (8.17%), Renaissance Technologies LLC (7.54%), Northern Trust Corp (4.06%), Connor Clark & Lunn Investment Management Ltd. (3.75%) and Brandes Investment Partners LP (3.65%). View Institutional Ownership Trends for PDL BioPharma.

Which major investors are selling PDL BioPharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Bank of America Corp DE, Acadian Asset Management LLC, Prudential Financial Inc., AQR Capital Management LLC, Skandinaviska Enskilda Banken AB publ and Renaissance Technologies LLC. View Insider Buying and Selling for PDL BioPharma.

Which major investors are buying PDL BioPharma stock?

PDLI stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Chicago Equity Partners LLC, Charles Schwab Investment Management Inc., Paloma Partners Management Co, Crestline Management LP, KBC Group NV, AXA and Royal Bank of Canada. View Insider Buying and Selling for PDL BioPharma.

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $2.57.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $293.50 million and generates $198.11 million in revenue each year. The biotechnology company earns $-68,860,000.00 in net income (profit) each year or $0.37 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe.View Additional Information About PDL BioPharma.

What is PDL BioPharma's official website?

The official website for PDL BioPharma is http://www.pdl.com/.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]


MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  427 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel